These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 21793097)

  • 1. Exposure to antipsychotic medications over a 4-year period among children who initiated antipsychotic treatment before their sixth birthday.
    Constantine RJ; Jentz S; Bengtson M; McPherson M; Andel R; Jones MB
    Pharmacoepidemiol Drug Saf; 2012 Feb; 21(2):152-60. PubMed ID: 21793097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early diagnoses and psychotherapeutic medication treatment experiences of a cohort of children under 6 years old who received antipsychotic treatment in Florida's Medicaid program.
    Constantine RJ; Tandon R; McPherson M; Andel R
    J Child Adolesc Psychopharmacol; 2011 Feb; 21(1):79-84. PubMed ID: 21288122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid population, 1998-2003.
    Morrato EH; Dodd S; Oderda G; Haxby DG; Allen R; Valuck RJ
    Clin Ther; 2007 Jan; 29(1):183-95. PubMed ID: 17379060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of adjunctive mood stabilizers on antipsychotic utilization pattern and health resource utilization for Medicaid enrollees with schizophrenia.
    Chen H; Kennedy WK; Dorfman JH; Fincham JE; Reeves J; Martin BC
    Curr Med Res Opin; 2007 Jun; 23(6):1351-65. PubMed ID: 17559734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atypical antipsychotic use among Medicaid-insured children and adolescents: duration, safety, and monitoring implications.
    Burcu M; Zito JM; Ibe A; Safer DJ
    J Child Adolesc Psychopharmacol; 2014 Apr; 24(3):112-9. PubMed ID: 24690011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New users of antipsychotic medications among children enrolled in TennCare.
    Cooper WO; Hickson GB; Fuchs C; Arbogast PG; Ray WA
    Arch Pediatr Adolesc Med; 2004 Aug; 158(8):753-9. PubMed ID: 15289247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Young People With Antipsychotic Medications in the United States.
    Olfson M; King M; Schoenbaum M
    JAMA Psychiatry; 2015 Sep; 72(9):867-74. PubMed ID: 26132724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utilization of pharmacologic treatment in youths with attention deficit/hyperactivity disorder in Medicaid database.
    Winterstein AG; Gerhard T; Shuster J; Zito J; Johnson M; Liu H; Saidi A
    Ann Pharmacother; 2008 Jan; 42(1):24-31. PubMed ID: 18042808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity.
    Research Units on Pediatric Psychopharmacology Autism Network
    Arch Gen Psychiatry; 2005 Nov; 62(11):1266-74. PubMed ID: 16275814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risperidone long-acting therapy prescribing patterns and their impact on early discontinuation of treatment in a large Medicaid population.
    Boaz TL; Constantine RJ; Robst J; Becker MA; Howe AM
    J Clin Psychiatry; 2011 Aug; 72(8):1079-85. PubMed ID: 21034690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continuity of methylphenidate treatment for attention-deficit/hyperactivity disorder.
    Marcus SC; Wan GJ; Kemner JE; Olfson M
    Arch Pediatr Adolesc Med; 2005 Jun; 159(6):572-8. PubMed ID: 15939858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use patterns for antipsychotic medications in medicaid patients with schizophrenia.
    McCombs JS; Nichol MB; Stimmel GL; Shi J; Smith RR
    J Clin Psychiatry; 1999; 60 Suppl 19():5-11; discussion 12-3. PubMed ID: 10507275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of death in elderly users of conventional vs. atypical antipsychotic medications.
    Wang PS; Schneeweiss S; Avorn J; Fischer MA; Mogun H; Solomon DH; Brookhart MA
    N Engl J Med; 2005 Dec; 353(22):2335-41. PubMed ID: 16319382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current concepts. Psychopharmacology in children.
    Biederman J; Jellinek MS
    N Engl J Med; 1984 Apr; 310(15):968-72. PubMed ID: 6142421
    [No Abstract]   [Full Text] [Related]  

  • 15. Using psychoactive medication to intervene in children's behaviour: an evidence-based practice?
    Parsonson BS
    J Prim Health Care; 2009 Mar; 1(1):6-10. PubMed ID: 20690480
    [No Abstract]   [Full Text] [Related]  

  • 16. Pervasive developmental disorders in Montreal, Quebec, Canada: prevalence and links with immunizations.
    Fombonne E; Zakarian R; Bennett A; Meng L; McLean-Heywood D
    Pediatrics; 2006 Jul; 118(1):e139-50. PubMed ID: 16818529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antipsychotic medications in children and adolescents.
    Findling RL; Grcevich SJ; Lopez I; Schulz SC
    J Clin Psychiatry; 1996; 57 Suppl 9():19-23. PubMed ID: 8823346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder.
    Klassen AF; Miller A; Fine S
    Pediatrics; 2004 Nov; 114(5):e541-7. PubMed ID: 15520087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs.
    Olfson M; Blanco C; Liu L; Moreno C; Laje G
    Arch Gen Psychiatry; 2006 Jun; 63(6):679-85. PubMed ID: 16754841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse events in children and adolescents treated with antipsychotic medications.
    Jerrell JM; McIntyre RS
    Hum Psychopharmacol; 2008 Jun; 23(4):283-90. PubMed ID: 18302312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.